Langues

16 November 2015 - Neurolixis Appoints Dr. Steven A. Johnson, PhD, as VP for Drug Development

Neurolixis Inc. offers a warm welcome to Steven A. Johnson as Vice-President for Drug Development.
Dr. Johnson has broad experience of neurology and neuropsychiatry and has managed pre-clinical and clinical development of CNS drug candidates. His expertise will be valuable as Neurolixis moves forward with development of its drug pipeline targeting Parkinson's disease and Rett syndrome.

See more information concerning Neurolixis' management team here.

Read the full press release:  pdf_symbol